Barrow Hanley Mewhinney & Strauss LLC Myriad Genetics Inc Transaction History
Barrow Hanley Mewhinney & Strauss LLC
- $26.4 Billion
- Q1 2025
A detailed history of Barrow Hanley Mewhinney & Strauss LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Barrow Hanley Mewhinney & Strauss LLC holds 56 shares of MYGN stock, worth $294. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56Holding current value
$294% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MYGN
# of Institutions
240Shares Held
95.3MCall Options Held
95.4KPut Options Held
18.2K-
Black Rock Inc. New York, NY15.2MShares$79.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.7MShares$56 Million0.0% of portfolio
-
State Street Corp Boston, MA5.27MShares$27.7 Million0.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN4.73MShares$24.9 Million0.98% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$24.1 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $423M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...